Takeda to commercialize next-generation hunter syndrome therapy through collaboration with jcr pharmaceuticals

Osaka, japan & ashiya, hyogo, japan--(business wire)--takeda and jcr announced an exclusive collaboration and license agreement to commercialize jr-141 for the treatment of hunter syndrome.

TAK Ratings Summary

TAK Quant Ranking